Merck, Pfizer Partner Diabetes Drug Gets FDA Ok
Source: Reuters
Dec 21, 2017
Steglatro, a new drug developed by Merck and Pfizer, won U.S. approval to treat type II diabetes.
The oral drug, which is an SGLT2 inhibitor, will compete with J&J’s Invokana, AstraZeneca’s Farxiga, and Eli Lilly and Boehringer Ingelheim’s Jardiance.
Steglatro was approved as a single therapy and in fixed-dose combinations with Merck’s diabetes drug Januvia or with metformin, an older generic treatment
Read the press release
Show Comments
Join the discussion
We welcome your thoughtful comments.
All comments will display your user name.
Comments
No one has commented on this page yet.
RSS feed for comments on this page | RSS feed for all comments